公开(公告)号：US20180244750A1

公开(公告)日：2018-08-30

申请号：US15773090

申请日：2016-11-02

申请人： Memgen, LLC

发明人： Mark J. Cantwell

IPC分类号： C07K14/705 ,  A61P35/00 ,  C12N7/00 ,  G01N33/574 ,  A61K39/395 ,  A61K38/17

CPC分类号： C07K14/70575 ,  A61K38/177 ,  A61K39/39558 ,  A61K48/00 ,  A61P35/00 ,  C12N7/00 ,  C12N2710/10021 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2710/10343 ,  G01N33/57492

摘要： Provided herein are methods of sensitizing cancer cells to treatment with inhibitors of the PD-1 pathway. Such methods comprise treatment of subject with a checkpoint inhibitor refractory cancer with an expression vector encoding a chimeric CD154.

公开(公告)号：US11594135B2

公开(公告)日：2023-02-28

申请号：US15772789

申请日：2016-11-02

申请人： Board of Regents, The University of Texas System ,  Memgen, LLC

发明人： Willem W. Overwijk ,  Manisha Singh ,  Patrick Hwu ,  Mark Cantwell

IPC分类号： A61K38/17 ,  C07K16/28 ,  A61P35/04 ,  A61K9/00 ,  C12N15/86 ,  A61K39/00 ,  A61K45/06 ,  G08G1/14 ,  G08G1/01 ,  H04L67/02 ,  H04W4/02 ,  H04L67/306

摘要： Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one immune checkpoint inhibitor and a chimeric CD 154 polypeptide. Also provided herein are methods of enhanced immune function.

公开(公告)号：US20200165339A1

公开(公告)日：2020-05-28

申请号：US15772789

申请日：2016-11-02

申请人： Board of Regents, The University of Texas System ,  Memgen, LLC

发明人： Willem W. OVERWIJK ,  Manisha SINGH ,  Patrick HWU ,  Mark CANTWELL

IPC分类号： C07K16/28 ,  A61K38/17 ,  A61K9/00 ,  A61P35/04 ,  C12N15/86

摘要： Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one immune checkpoint inhibitor and a chimeric CD 154 polypeptide. Also provided herein are methods of enhanced immune function.

公开(公告)号：US20180169241A1

公开(公告)日：2018-06-21

申请号：US15843603

申请日：2017-12-15

申请人： Memgen, LLC

发明人： Mark J. Cantwell

IPC分类号： A61K39/42 ,  C07K14/705 ,  A61P35/00

摘要： Disclosed are oncolytic viruses comprising chimeric human/mouse CD40 ligands. The chimeric human/mouse CD40 ligand may be MEM40. The oncolytic virus may be replication competent. The oncolytic virus may be an oncolytic herpes simplex virus. Also disclosed are methods comprising administering an oncolytic virus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from cancer.

公开(公告)号：US11298420B2

公开(公告)日：2022-04-12

申请号：US15843603

申请日：2017-12-15

申请人： Memgen, LLC

发明人： Mark J. Cantwell

IPC分类号： A61K39/42 ,  A61K38/17 ,  C07K14/705 ,  A61P35/00 ,  A61K39/00

摘要： Disclosed are oncolytic viruses comprising chimeric human/mouse CD40 ligands. The chimeric human/mouse CD40 ligand may be MEM40. The oncolytic virus may be replication competent. The oncolytic virus may be an oncolytic herpes simplex virus. Also disclosed are methods comprising administering an oncolytic virus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from cancer.

公开(公告)号：US20210268090A1

公开(公告)日：2021-09-02

申请号：US17253927

申请日：2019-06-18

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  MEMGEN, LLC

发明人： AMER A. BEG ,  SCOTT J. ANTONIA ,  MARK J. CANTWELL

IPC分类号： A61K39/00 ,  A61K35/28 ,  C07K14/56 ,  C07K14/705 ,  A61P35/00 ,  A61K35/761 ,  A61K35/15 ,  C12N5/0784 ,  C12N7/00

摘要： The invention concerns APCs, such as DCs, comprising a combination of an exogenous type I interferon and an exogenous CD40-L or one or more heterologous nucleic acid sequences encoding a combination of an exogenous type I IFN and an exogenous CD40-L, such as a combination of IFNβ and CD40-L; and methods for treating a malignancy by administering such APCs to a subject in need thereof. In certain embodiments, a subject is treated with an irradiation therapy before administering the APCs, such as DCs, of the invention. The invention also concerns an oncolytic virus comprising a combination of a type I IFN and CD40-L or one or more nucleic acid sequences encoding a combination of a type I IFN and CD40-L, such as a combination of IFNβ and CD40-L; and methods for treating a malignancy by administering such oncolytic virus to a subject in need thereof.

公开(公告)号：US20180169271A1

公开(公告)日：2018-06-21

申请号：US15847612

申请日：2017-12-19

申请人： Memgen, LLC ,  DNAtrix

发明人： Mark J. Cantwell ,  Winnie M. Chan ,  Brett Ewald ,  Joan M. Robbins

IPC分类号： A61K48/00 ,  C07K14/705 ,  C12N15/86 ,  A61K38/17 ,  A61K45/06

CPC分类号： A61K48/0058 ,  A61K35/761 ,  A61K38/17 ,  A61K38/177 ,  A61K45/06 ,  C07K14/70575 ,  C12N15/86 ,  C12N2710/10033 ,  C12N2710/10043 ,  C12N2830/60

摘要： Disclosed are replication-competent oncolytic adenoviruses, comprising chimeric human/mouse CD40 ligands. The oncolytic adenoviruses may be replication competent. The chimeric human/mouse CD40 ligand may be MEM40. Also disclosed are methods comprising administering a replication competent oncolytic adenovirus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from a cancer.